Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in GILD — Gilead Sciences, Inc.

CIK 1423053 MIAMI, FL
Back to GILD Full portfolio

Position in GILD

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$439,719,294
-$115,277,828 QoQ
Shares Held
3,480,444
-12.6% QoQ
Ownership
0.281%
of shares outstanding
% of Portfolio
0.29%
of 13F equity value
Holder Rank
#46
of 2,275 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in GILD Over Time

Shares Held

Position Value (USD)

Derivatives in GILD

reported options exposure · as of Jun 30, 2026
CallValue
$136,333,494
CallShares
1,079,100
PutValue
$128,424,610
PutShares
1,016,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $3,979,998,649 across 21 Drug Manufacturers - General names. GILD ranks #3 (11.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 945,456 $1,134,008,383
2 ABBV
AbbVie Inc.
 3,169,783 $797,644,194
3 GILD
Gilead Sciences, Inc.
This page 		3,480,444 $439,719,294
4 JNJ
Johnson & Johnson
 1,500,832 $381,166,302
5 AMGN
Amgen Inc
 703,984 $254,926,685
6 MRK
Merck & Co., Inc.
 1,933,667 $248,476,209
7 AZN
Astrazeneca PLC
 970,043 $183,939,553
8 PFE
Pfizer Inc
 6,191,186 $149,083,758

All Filings in GILD

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $128,424,610 1,016,500
2026-06-30 $439,719,294 3,480,444
2026-06-30 $136,333,494 1,079,100
2026-03-31 $206,434,844 1,481,200
2026-03-31 $83,663,811 600,300
2026-03-31 $554,997,122 3,982,185
2025-12-31 $477,154,204 3,887,520
2025-12-31 $138,757,570 1,130,500
2025-12-31 $127,551,408 1,039,200
2025-09-30 $136,585,500 1,230,500
2025-09-30 $127,294,800 1,146,800
2025-09-30 $578,050,926 5,207,666
2025-06-30 $179,953,097 1,623,100
2025-06-30 $606,519,324 5,470,545
2025-06-30 $171,471,542 1,546,600
2025-03-31 $116,016,570 1,035,400
2025-03-31 $138,236,085 1,233,700
2025-03-31 $602,152,441 5,373,962
2024-12-31 $433,759,266 4,695,889
2024-12-31 $71,051,004 769,200
2024-12-31 $128,135,664 1,387,200
2024-09-30 $109,780,096 1,309,400
2024-09-30 $420,701,825 5,017,913
2024-09-30 $100,180,416 1,194,900
2024-06-30 $105,913,257 1,543,700
2024-06-30 $78,469,257 1,143,700
2024-06-30 $19,100,132 278,387
2024-03-31 $389,814,084 5,321,694
2024-03-31 $116,987,575 1,597,100
2024-03-31 $64,848,225 885,300
2023-12-31 $32,501,535 401,204
2023-12-31 $84,760,763 1,046,300
2023-12-31 $98,621,574 1,217,400
2023-09-30 $98,770,920 1,318,000
2023-09-30 $29,370,184 391,916
2023-09-30 $106,961,862 1,427,300
2023-06-30 $80,121,972 1,039,600
2023-06-30 $121,801,428 1,580,400
2023-06-30 $23,033,602 298,866
2023-03-31 $91,233,812 1,099,600
2023-03-31 $120,812,617 1,456,100
2023-03-31 $186,825,125 2,251,719
2022-12-31 $141,781,275 1,651,500
2022-12-31 $184,148,250 2,145,000
2022-12-31 $142,083,037 1,655,015
2022-09-30 $172,084,255 2,789,500
2022-09-30 $21,063,864 341,447
2022-09-30 $115,736,609 1,876,100
2022-06-30 $130,653,978 2,113,800
2022-06-30 $221,032,560 3,576,000

Report a Problem

Category
Description
Email (optional, for follow-up)